English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The original article contained incorrect terminology for one of the cardiac measures; throughout the manuscript and supplementary information ‘ intraventricular septum wall thickness ’ should have been given as ‘ interventricular septum wall thickness ’. Corrections should also be noted for Tables 1 and 4: in the Table 1 legend ‘Low risk – Neither above at baseline’ should read ‘Low risk – Neither above threshold at baseline’ ; in Table 4, the rows ‘Mild: eGFR > 60 to < 90 ml/min/1.73 m 2 ’ and ‘Moderate: eGFR > 30 to < 60 ml/min/1.73 m 2 ’ should read ‘Mild: eGFR ≥ 60 to < 90 ml/min/1.73 m 2 ’ and ‘Moderate: eGFR ≥ 30 to < 60 ml/min/1.73 m 2 ’, respectively. The original article also contained a mistake in the text of the Pharmacokinetics sub-section of Results; ‘There were no apparent differences in revusiran C max between patients with mild (eGFR: 30 and < 60 ml/min/1.73 m 2 ) or moderate (eGFR: 60 to < 90 ml/min/1.73 m 2 ) renal impairment when compared with patients with normal (eGFR: ≥ 90 ml/min/1.73 m 2 ) renal function at Weeks 0, 26, and 52 (p > 0.20) (Supplementary Fig. 6)’ should read ‘There were no apparent differences in revusiran C max between patients with mild (eGFR: ≥ 60 to < 90 ml/min/1.73 m 2 ) or moderate (eGFR: ≥ 30 and < 60 ml/min/1.73 m 2 ) renal impairment when compared with patients with normal (eGFR: ≥ 90 ml/min/1.73 m 2 ) renal function at Weeks 0, 26, and 52 (p > 0.20) (Supplementary Fig. 6)’ .

cardiovascular drugs and therapy

Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)